Issued 2026-09-16 at $3.00 · now $3.00 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, PRME has typically landed between $2.01 and $4.28 — a range of −33.0% to +42.5% from the issuance price $3.00.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
958 overlapping 1 month windows · 2022-10-20 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($3.00) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where PRME has typically landed a month from the 2026-09-16 close of $3 — the range is history, not a prediction.
- now $3 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.85 (-5.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.4–$3.3
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.01–$4.28
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-10-15 | −47.7% | −47.7% | +0.0% |
| 2023-09-13 | −47.3% | −47.3% | +0.2% |
| 2025-03-07 | −45.8% | −45.8% | +0.0% |
| 3 best | |||
| 2025-06-11 | +214.4% | −4.6% | +214.4% |
| 2025-06-05 | +201.5% | +0.0% | +201.5% |
| 2025-06-12 | +193.8% | +0.0% | +229.5% |
958 overlapping windows · 2022-10-20 – 2026-09-16 · not cherry-picked
Pending catalysts
- January 2030 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-01 | ARCH Venture Partners X, LLC | tenPercentOwner | Purchase | 3,030,300 @ $3.30 | $10.0M | +94.7% of holding | −25.8% | −18.4% | 6,230,300 | Form 4 · filed same day |
| 2025-08-01 | ARCH Venture Partners XII, LLC | director | Purchase | 3,030,300 @ $3.30 | $10.0M | +94.7% of holding | −25.8% | −18.4% | 6,230,300 | Form 4 · filed same day |
| 2025-08-01 | NELSEN ROBERT | director | Purchase | 3,030,300 @ $3.30 | $10.0M | +94.7% of holding | −25.8% | −18.4% | 6,230,300 | Form 4 · filed same day |
| 2025-08-01 | GV 2021 GP, L.L.C. | tenPercentOwner | Purchase | 1,500,000 @ $3.30 | $5.0M | +85.1% of holding | −25.8% | −18.4% | 3,262,440 | Form 4 · filed 4 days after the trade |
| 2025-06-30 | Liu David R. | tenPercentOwner | Purchase | 21,000 @ $2.52 | $53K | +0.1% of holding | +56.0% | +24.5% | 20,240,945 | Form 4 · filed 1 day after the trade |
| 2025-06-23 | Liu David R. | tenPercentOwner | Purchase | 21,000 @ $2.16 | $45K | +0.1% of holding | +109.1% | +54.5% | 20,219,945 | Form 4 · filed same day |
| 2025-06-16 | Liu David R. | tenPercentOwner | Purchase | 21,000 @ $1.49 | $31K | +0.1% of holding | +155.5% | +155.7% | 20,198,945 | Form 4 · filed same day |
| 2025-06-11 | Liu David R. | tenPercentOwner | Purchase | 21,000 @ $1.60 | $34K | +0.1% of holding | +210.2% | +168.0% | 20,177,945 | Form 4 · filed 1 day after the trade |
| 2025-05-21 | Reine Allan | director | Purchase | 125,000 @ $1.18 | $147K | ownership Δ n/a | +81.3% | +203.6% | 125,000 | Form 4 · filed 1 day after the trade |
| 2025-05-21 | LEE ANN L. | officer | Purchase | 100,000 @ $1.13 | $113K | ownership Δ n/a | +81.3% | +203.6% | 100,000 | Form 4 · filed 1 day after the trade |
| 2025-05-20 | Brudnick Richard | director | Purchase | 20,000 @ $1.19 | $24K | ownership Δ n/a | +74.9% | +188.9% | 20,000 | Form 4 · filed 2 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
144 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Foster-Cheek Kaye I | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | Cahill Thomas | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | Schenkein David P | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | Chung Wendy | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | NELSEN ROBERT | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | Marrazzo Jeffrey D | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-06-05 | Kelly Michael Aaron | director | Award / grant | 75,000 | 75,000 | Form 4 |
| 2026-04-16 | Makhni Svetlana Ni | officer | Award / grant | 800,000 | 800,000 | Form 4 |
| 2026-02-26 | Reine Allan | director | Award / grant | 1,300,000 | 1,300,000 | Form 4 |
| 2026-02-23 | LEE ANN L. | officer | Award / grant | 375,000 | 375,000 | Form 4 |
| 2026-02-23 | Alenson Carman | officer | Award / grant | 140,000 | 140,000 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Disposition | 9,006 | 0 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Award / grant | 9,006 | 9,006 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Disposition | 39,062 | 0 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Award / grant | 39,062 | 39,062 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Disposition | 45,000 | 0 | Form 4 |
| 2025-08-01 | Foster-Cheek Kaye I | director | Award / grant | 45,000 | 45,000 | Form 4 |
| 2025-08-01 | LEE ANN L. | officer | Disposition | 180,995 | 0 | Form 4 |
| 2025-08-01 | LEE ANN L. | officer | Award / grant | 180,995 | 180,995 | Form 4 |
| 2025-08-01 | LEE ANN L. | officer | Disposition | 180,995 | 0 | Form 4 |
| 2025-08-01 | LEE ANN L. | officer | Award / grant | 180,995 | 180,995 | Form 4 |
| 2025-08-01 | Reine Allan | director | Disposition | 850,000 | 0 | Form 4 |
| 2025-08-01 | Reine Allan | director | Award / grant | 850,000 | 850,000 | Form 4 |
| 2025-08-01 | Marrazzo Jeffrey D | director | Award / grant | 92,000 | 92,000 | Form 4 |
| 2025-08-01 | Marrazzo Jeffrey D | director | Disposition | 250,000 | 0 | Form 4 |
| 2025-08-01 | Marrazzo Jeffrey D | director | Award / grant | 250,000 | 250,000 | Form 4 |
| 2025-08-01 | Marrazzo Jeffrey D | director | Disposition | 45,000 | 0 | Form 4 |
| 2025-08-01 | Marrazzo Jeffrey D | director | Award / grant | 45,000 | 45,000 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Disposition | 13,510 | 0 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Award / grant | 13,510 | 13,510 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Disposition | 9,006 | 0 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Award / grant | 9,006 | 9,006 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Disposition | 39,062 | 0 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Award / grant | 39,062 | 39,062 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Disposition | 45,000 | 0 | Form 4 |
| 2025-08-01 | Kelly Michael Aaron | director | Award / grant | 45,000 | 45,000 | Form 4 |
| 2025-08-01 | Schenkein David P | director | Disposition | 39,062 | 0 | Form 4 |
| 2025-08-01 | Schenkein David P | director | Award / grant | 39,062 | 39,062 | Form 4 |
| 2025-08-01 | Schenkein David P | director | Disposition | 45,000 | 0 | Form 4 |
| 2025-08-01 | Schenkein David P | director | Award / grant | 45,000 | 45,000 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.